Stella Pharma Corporation (4888.T)
JPY 328.0
(0.31%)
JPY 328.0
(0.31%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -760.3 Million JPY | 5.76% |
| 2022 | -806.77 Million JPY | -8.74% |
| 2021 | -741.9 Million JPY | -9.01% |
| 2020 | -680.56 Million JPY | 28.44% |
| 2019 | -951 Million JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -166.9 Million JPY | 43.1% |
| 2023 Q2 | -138.17 Million JPY | 15.26% |
| 2023 FY | -760.3 Million JPY | 5.76% |
| 2023 Q4 | -293.33 Million JPY | -76.99% |
| 2023 Q3 | -165.73 Million JPY | -19.95% |
| 2023 Q1 | -163.06 Million JPY | 46.32% |
| 2022 Q3 | -136.45 Million JPY | 20.22% |
| 2022 FY | -806.77 Million JPY | -8.74% |
| 2022 Q4 | -303.77 Million JPY | -122.61% |
| 2022 Q2 | -171.03 Million JPY | 0.0% |
| 2021 FY | -741.9 Million JPY | -9.01% |
| 2020 FY | -680.56 Million JPY | 28.44% |
| 2019 FY | -951 Million JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 596.82 Million JPY | 227.391% |
| PRISM BioLab Co.,LTD | -496.86 Million JPY | -53.019% |
| GNI Group Ltd. | 13.1 Billion JPY | 105.8% |
| Linical Co., Ltd. | 725.72 Million JPY | 204.764% |
| Trans Genic Inc. | 89.43 Million JPY | 950.105% |
| MEDINET Co., Ltd. | -1.42 Billion JPY | 46.681% |
| Soiken Holdings Inc. | -610 Million JPY | -24.638% |
| Cytori Cell Research Institute, Inc. | -772.74 Million JPY | 1.61% |
| AnGes, Inc. | -11.96 Billion JPY | 93.647% |
| OncoTherapy Science, Inc. | -1.12 Billion JPY | 32.164% |
| Nxera Pharma Co., Ltd. | -9.52 Billion JPY | 92.019% |
| Immuno-Biological Laboratories Co., Ltd. | 104.29 Million JPY | 828.962% |
| NanoCarrier Co., Ltd. | -864.41 Million JPY | 12.045% |
| Carna Biosciences, Inc. | -1.11 Billion JPY | 31.932% |
| CanBas Co., Ltd. | -1.26 Billion JPY | 39.754% |
| D. Western Therapeutics Institute, Inc. | -798.55 Million JPY | 4.791% |
| RaQualia Pharma Inc. | -337.36 Million JPY | -125.364% |
| Chiome Bioscience Inc. | -1.2 Billion JPY | 36.913% |
| Kidswell Bio Corporation | -1.33 Billion JPY | 43.074% |
| PeptiDream Inc. | 6.77 Billion JPY | 111.225% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 60.606% |
| Ribomic Inc. | -1.11 Billion JPY | 31.885% |
| SanBio Company Limited | -4.53 Billion JPY | 83.25% |
| Healios K.K. | -3.37 Billion JPY | 77.499% |
| BrightPath Biotherapeutics Co., Ltd. | -1.15 Billion JPY | 34.178% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 45.44% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 45.809% |
| StemRIM | -2.07 Billion JPY | 63.377% |
| CellSource Co., Ltd. | 1.22 Billion JPY | 162.243% |
| FunPep Company Limited | -994 Million JPY | 23.511% |
| Kringle Pharma, Inc. | -888.76 Million JPY | 14.454% |
| TMS Co., Ltd. | -943.25 Million JPY | 19.396% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | 1.946% |
| Cuorips Inc. | -588.48 Million JPY | -29.196% |
| K Pharma,Inc. | 366.05 Million JPY | 307.7% |
| Takara Bio Inc. | 3 Billion JPY | 125.318% |
| ReproCELL Incorporated | -409.29 Million JPY | -85.759% |
| PhoenixBio Co., Ltd. | 11.06 Million JPY | 6972.458% |
| StemCell Institute Inc. | 413.75 Million JPY | 283.754% |
| Japan Tissue Engineering Co., Ltd. | 144.5 Million JPY | 626.134% |
| CellSeed Inc. | -697.77 Million JPY | -8.96% |